TheraSphere — a therapy that consists of millions of microscopic, radioactive glass microspheres (20-30 microns diameter) — is infused into the arteries that feed inoperable liver tumors, bathing the malignancy in high levels of extremely localized radiation. In some studies of highly selected patients, the response rates and stabilization rates ranged between 20-40 percent. No survival benefit has been demonstrated other than arguably for hepatocellular carcinoma and colorectal cancer metastases. However, for metastases from the cancers, including Yttrium followed by transplantation or immunologic therapy.
Andrew S Kennedy, Riad Salem Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer journal Sudbury Mass (2010) Volume: 16, Issue: 2, Pages: 163-175Hua-Yu Yang, Bao Jin, Gang Xu, Le-Jia Sun, Shun-Da Du, Yi-Lei Mao, Transarterial radioembolization with Yttrium-90: current status and future prospects, Gastroenterology Report, Volume 8, Issue 2, April 2020, Pages 164–165